AI Article Synopsis

  • Immunoglobulin substitution therapy is critical for patients with primary antibody deficiencies, with a new 20% subcutaneous immunoglobulin (SCIG) option using rapid-push application being evaluated in the Czech Hizentra Noninterventional Study (CHHINSTRAP).
  • The study aims to assess patient satisfaction, tolerability, and efficacy after switching from previous intravenous (IVIG) or SCIG treatments to the new 20% SCIG.
  • Preliminary findings show improved serum IgG levels and a decrease in infections and hospitalizations, indicating increased convenience and satisfaction among patients after the switch.

Article Abstract

Purpose: Immunoglobulin substitution therapy is an essential therapeutic approach for patients with primary antibody deficiencies. Different methods of administration, including intravenous immunoglobulin (IVIG) or subcutaneous immunoglobulin (SCIG) preparations, provide effective and tolerable treatment and enable the adjustment of therapy to patients' needs. A new 20% SCIG represents a new therapeutic option and a new route of administration using rapid-push application. The aim of the Czech Hizentra Noninterventional Study With Rapid Push (CHHINSTRAP) is to evaluate patient satisfaction with as well as the tolerability and efficacy of nonmedical switch to 20% SCIG from previous treatment with IVIG or SCIG and rapid push as a new way to administer SCIG. CHHINSTRAP is the first Phase IV, noninterventional, open-label, prospective, multicentric study of this type conducted in Central and Eastern Europe.

Methods: Primary end points, including efficacy, adverse effects, convenience of use, and overall satisfaction, were evaluated by Treatment Satisfaction Questionnaire for Medication version II. Secondary end points, such as serum IgG trough levels, infusion duration, number of application sites, frequency of infections, related hospital admissions, and antibiotic consumption, were obtained from patients at each follow-up visit.

Findings: Together, 50 eligible patients with primary antibody deficiency were switched from SCIG or IVIG to an equivalent dose of 20% SCIG and were followed up for 12 months during 5 consecutive visits. The results indicate that patients switched from previous IVIG or SCIG preparations had significantly higher serum trough IgG levels and a lower incidence of infections and related events, such as hospital admissions or consumption of antibiotics. These findings were also reflected in gradually increasing convenience of use and overall satisfaction reported by patients. Apart from duration of application, no differences were found between patients previously receiving SCIG or IVIG. Moreover, our study found a high level of safety of 20% SCIG rapid push, which was comparable to other preparations and application methods.

Implications: On the basis of the results of CHHINSTRAP study, we conclude that 20% SCIG is a tolerable and effective immunoglobulin preparation, representing a new therapeutic approach in patients with primary antibody deficiencies. Its efficacy and tolerability have been found in patients on nonmedical switch from previous treatment with IVIG or SCIG.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinthera.2019.08.013DOI Listing

Publication Analysis

Top Keywords

20% scig
20
rapid push
16
patients primary
12
primary antibody
12
scig
12
ivig scig
12
czech hizentra
8
hizentra noninterventional
8
noninterventional study
8
study rapid
8

Similar Publications

Article Synopsis
  • Primary immunodeficiency diseases (PIDs) are genetic immune system disorders requiring lifelong immunoglobulin replacement therapy, usually delivered through IVIG or SCIG infusions.
  • Ig20Gly, a 20% immune globulin solution, is a replacement therapy approved for various age groups, with recent approvals for manual administration in Europe aimed at simplifying the process.
  • Manual administration of Ig20Gly allows for faster infusion rates, similar safety and satisfaction levels compared to infusion pumps, and potential cost savings for healthcare systems due to lower equipment and nursing needs.
View Article and Find Full Text PDF

Introduction: Few studies have pointed to the possible role of infectious diseases in triggering Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). Given the association of Hepatitis E Virus (HEV) with Guillain Barrè syndrome, we conducted a case-control study to determine the possible association of HEV infection with CIDP, analyzing possible risk factors for acquiring HEV infection in both CIDP patients and controls.

Materials And Methods: 82 CIDP and 260 from the general population have provided some personal information (demographics, anamnestic data and recognized risk factors for HEV infection) and underwent venipuncture blood sampling for virological assays testing for anti-HEV IgG and IgM with ELISA and RNA-HEV performing RT-PCR.

View Article and Find Full Text PDF

Background: Here, the perspective of patients with primary and secondary immunodeficiency receiving subcutaneous immunoglobulin (SCIg) via introductory smaller size pre-filled syringes (PFS) or vials were compared.

Methods: An online survey was conducted in Canada by the Association des Patients Immunodéficients du Québec (APIQ) (10/2020-03/2021). Survey questions included: reasons for choosing SCIg packaging and administration methods, training experiences, infusion characteristics, and switching methods.

View Article and Find Full Text PDF

Background And Purpose: Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune disease with humoral and cellular autoimmunity causing demyelination of peripheral nerves, commonly treated with intravenous immunoglobulins (IVIg). The neonatal Fc receptor (FcRn), encoded by the FCGRT gene, prevents the degradation of immunoglobulin G (IgG) by recycling circulating IgG. A variable number of tandem repeat (VNTR) polymorphism in the promoter region of the FCGRT gene is associated with different expression levels of mRNA and protein.

View Article and Find Full Text PDF

Subcutaneous immunoglobulin therapy for adult patients with primary immunodeficiency disease: Qatar experience.

Qatar Med J

November 2023

Adult Allergy and Immunology Section, Department of Medicine, Hamad Medical Corporation, Doha, Qatar. Email:

Introduction: Subcutaneous immunoglobulin (SCIG) and intravenous immunoglobulin (IVIG) are used for the treatment of primary immunodeficiency (PIDD). SCIG is as effective as IVIG in preventing infections. However, SCIG has advantages over IVIG as it causes fewer systemic reactions and can be infused at home by the patient leading to improved quality of life.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!